Ludwig Enterprises, Inc. (LUDG): Cash & Equivalents
$0
As of 2025-12-31
$18.3K
As of 2026-03-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $217 | n/a | 2026-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Ludwig Enterprises, Inc. (LUDG) | 2025-12-31 | $0 | -100.0% |
| First Choice Healthcare Solutions, Inc. (FCHS) | 2025-12-31 | $5.9K | -70.4% |
| BioNexus Gene Lab Corp (BGLC) | 2025-12-31 | $2.49M | -13.9% |
| Aclarion, Inc. (ACON) | 2025-12-31 | $12.02M | n/m |
| YD Bio Ltd (YDES) | 2025-12-31 | $6.01M | +91.8% |
| American Shared Hospital Services (AMS) | 2025-12-31 | $3.46M | -68.6% |
| Exagen Inc. (XGN) | 2025-12-31 | $32.22M | +46.2% |
| Biodesix Inc (BDSX) | 2025-12-31 | $18.99M | -27.7% |
| Sera Prognostics, Inc. (SERA) | 2025-12-31 | $3.94M | -2.4% |
Compare LUDG, FCHS, BGLC, ACON side by side · Screen every company in Services-Medical Laboratories ↗